KA/EN
Register
Medicines reference
Search
Search
Active substance

Xylazine

Favourites

Alpha-2 adrenoceptor agonist. Registered in Georgia: 3 veterinary products. Forms: solution.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Xylazine
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.5–1 mg/kg Dog Sedation Intravenous once
Xylazin bio Romanian SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Xylazin bio 2% solution for injection - current Romanian authorisation and SPC
EU Veterinary Medicines Information / Romanian authority, 2021
1–3 mg/kg Dog Sedation Intramuscular once
Rometar Czech SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Rometar 20 mg/ml solution for injection - current Czech authorisation and SPC
EU Veterinary Medicines Information / Czech USKVBL, 2026
1–2 mg/kg Cat Sedation Intramuscular / Subcutaneous once
Rometar Czech SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Rometar 20 mg/ml solution for injection - current Czech authorisation and SPC
EU Veterinary Medicines Information / Czech USKVBL, 2026
Before use

Safety information

Known Contraindications

  • Critical
    Do not use in the last trimester of pregnancy (uterine contractions).
    Sources: Czech SPC
  • Critical
    Do not use with gastric dilatation or torsion or oesophageal obstruction.
    Sources: Czech SPC
  • Critical
    Dogs and cats: do not use with diabetes mellitus (xylazine raises blood glucose).
    Sources: Czech SPC
  • Critical
    Do not use if hypersensitive to xylazine or excipients.
    Sources: Czech SPC
  • Critical
    Dogs and cats: do not use in illness with vomiting. Do not combine with neuroleptics.
    Sources: Czech SPC
  • Warning
    Heart or circulatory disease: use with caution (Rometar); contraindicated in cardiopulmonary disease (Xylazin bio 2%).
    Sources: Czech SPC
  • Warning
    Respiratory disease: use with caution; contraindicated in cardiopulmonary disease (Xylazin bio 2%).
    Sources: Czech SPC
  • Caution
    Liver dysfunction: use with caution.
    Sources: Czech SPC
  • Caution
    Kidney dysfunction: use with caution.
    Sources: Czech SPC
Latin name
Xylazine
Georgian name
ქსილაზინი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
3 of 3 forms
Products
Rometar, Xyla, Xylazin bio
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
All forms and registration3

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Rometar 20 mg/ml, Solution

xylazine 20 mg/ml, solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Label-concordant IM sedation and anaesthetic premedication in appropriately selected dogs, with balanced analgesia for painful procedures
6.7/10
Situational / acceptable
vetman assessment

Rometar

20 mg/ml, xylazine 20 mg/ml, solution for injection
Assessed clinical scopeDog · Label-concordant IM sedation and anaesthetic premedication in appropriately selected dogs, with balanced analgesia for painful procedures · Intramuscular
Care settingVeterinary-only administration after pre-anaesthetic assessment, exact weight/concentration calculation and protocol reconciliation; airway, oxygen, cardiovascular/ventilation/temperature monitoring and supervised recovery immediately available
vetman score 6.7/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

An effective authorised canine sedative with a clear exact dose, but not a benign or complete anaesthetic. Its cardiovascular/respiratory burden and older protocol make careful selection, balanced analgesia and full monitoring decisive.

Regulatory and scientific credibility8.0/10

The exact 50 ml product has current Czech and Georgian veterinary registration, regulator-visible identity and a transparent exact instruction; separate Slovak authorisation and current same-strength controls support class applicability. The legacy dossier and limited exact-product outcome/pharmacovigilance publications cap the score.

Clinical efficacy7.0/10

Xylazine reliably produces dose-dependent canine sedation and muscle relaxation, and direct physiologic studies confirm effect. Responses vary, modern guidance often prefers more selective alpha-2 agonists, and xylazine alone does not supply dependable surgical analgesia.

Safety and tolerability5.0/10

Clinically important bradycardia/AV block, biphasic blood pressure, reduced cardiac output, arrhythmia, respiratory depression, emesis, hypothermia, hyperglycaemia and rare arrest require strict selection and monitoring. Airway disease, shock, cardiac/respiratory/hepatic/renal disease, diabetes, seizures and GI obstruction are hard exclusions.

Clinical practicality7.0/10

A single IM injection and familiar 20 mg/ml concentration are operationally simple, but 0.05–0.15 ml/kg must be measured accurately and cannot be titrated IV on this exact label. Pre-assessment, fasting plan, combination-dose reduction, monitoring and recovery staffing are substantial requirements.

Full-course cost-effectiveness-

Current Georgian full-course price and vial-wastage data were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Use only after examination in a monitored veterinary setting with oxygen, airway/ventilation and cardiovascular resuscitation capability. Record exact weight, concentration, route, total dose, co-drugs and times.
  • Do not use with GI obstruction, significant cardiac disease or ventricular arrhythmia, respiratory insufficiency, hepatic/renal impairment, seizure history, hypotension/shock or diabetes; avoid in puppies/kittens under six weeks.
  • Exact dose is 1–3 mg/kg IM once; there is no dog IV dose on this Rometar label. Use the lowest effective dose, especially in older, obese, large or compromised dogs, and do not automatically give the printed one-third to one-half top-up.
  • Monitor ECG/rhythm, heart rate, blood pressure, oxygenation, ventilation, temperature and sedation depth continuously through recovery. Bradycardia/AV block can be severe, and an initial pressure rise may be followed by hypotension and reduced cardiac output.
  • Vomiting commonly occurs within minutes. Use an individual fasting plan, protect the airway and position/recover the patient to reduce regurgitation and aspiration risk; fasting does not eliminate that risk.
  • Xylazine alone is not reliable surgical analgesia or general anaesthesia. For painful procedures provide local/general anaesthesia and multimodal analgesia, reducing all interacting sedative/anaesthetic doses to effect.
  • Other CNS depressants are additive. Do not combine with epinephrine or other sympathomimetics because ventricular arrhythmia may follow; reconcile every co-drug and avoid casual protocol substitution.
  • Brachycephalic airway disease can cause life-threatening dyspnoea; deep-chested breeds may bloat. Pregnancy requires benefit–risk assessment and late-pregnancy use is contraindicated except at parturition.
  • An alpha-2 antagonist may reverse selected effects but does not erase aspiration, hypoxaemia, arrhythmia, temperature, fluid or co-anaesthetic risk. Calculate the antagonist protocol and continue monitoring for pain, haemodynamic change or re-sedation.
  • Prevent accidental self-injection, ingestion and skin/eye/mucosal exposure. After exposure seek urgent medical advice and do not drive; pregnant handlers need special caution. Store below 25°C, protect from light and discard 28 days after opening.
Assessment sources
  1. Rometar Czech SPC2026
  2. Rometar exact instruction2026
  3. Xylexx VMD control2025
  4. AnaSed FDA control1992
  5. AAHA anaesthesia 20202020
  6. ACVAA monitoring 20252025
  7. Canine cardiopulmonary1975
  8. Canine xylazine ketamine1986
  9. Canine antagonism2009
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Label-concordant IM or SC sedation and anaesthetic premedication in appropriately selected cats, with balanced analgesia for painful procedures
6.4/10
Situational / acceptable
vetman assessment

Rometar

20 mg/ml, xylazine 20 mg/ml, solution for injection
Assessed clinical scopeCat · Label-concordant IM or SC sedation and anaesthetic premedication in appropriately selected cats, with balanced analgesia for painful procedures · IM,SC
Care settingVeterinary-only administration after pre-anaesthetic assessment, exact weight/concentration calculation and protocol reconciliation; airway, oxygen, cardiovascular/ventilation/temperature monitoring and supervised recovery immediately available
vetman score 6.4/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

An authorised effective feline sedative whose frequent emesis, respiratory/cardiovascular burden and small-volume dosing make it a conditional monitored option rather than a routine default.

Regulatory and scientific credibility8.0/10

The exact 50 ml product has current Czech and Georgian veterinary registration, regulator-visible identity and a transparent exact instruction; separate Slovak authorisation and current same-strength controls support class applicability. The legacy dossier and limited exact-product outcome/pharmacovigilance publications cap the score.

Clinical efficacy6.5/10

Authorised exact labeling and established alpha-2 pharmacology support feline sedation, but direct modern feline clinical-outcome evidence is thinner and response at the exact upper dose includes respiratory depression. It is premedication, not complete anaesthesia or stand-alone surgical analgesia.

Safety and tolerability4.5/10

Frequent onset emesis plus bradycardia/AV block, pressure and cardiac-output change, respiratory depression at the upper label dose, hyperglycaemia, hypothermia, polyuria and rare arrest create a narrow safety margin. Late pregnancy also carries a specific uterine/premature-labour hazard.

Clinical practicality6.5/10

A single IM/SC injection is simple, but a 0.05–0.1 ml/kg volume can be very small and handling plus vomiting/airway preparation matter. Individual fasting, combination-dose reduction, continuous monitoring and full supervised recovery limit convenience despite one administration.

Full-course cost-effectiveness-

Current Georgian full-course price and vial-wastage data were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Use only after examination in a monitored veterinary setting with oxygen, airway/ventilation and cardiovascular resuscitation capability. Record exact weight, concentration, route, total dose, co-drugs and times.
  • Do not use with GI obstruction, significant cardiac disease or ventricular arrhythmia, respiratory insufficiency, hepatic/renal impairment, seizure history, hypotension/shock or diabetes; avoid in puppies/kittens under six weeks.
  • Exact dose is 1–2 mg/kg IM or SC once; the upper limit may depress respiration. Measure the small volume accurately, use the lowest effective dose and do not automatically give the printed one-third to one-half top-up.
  • Monitor ECG/rhythm, heart rate, blood pressure, oxygenation, ventilation, temperature and sedation depth continuously through recovery. Bradycardia/AV block can be severe, and an initial pressure rise may be followed by hypotension and reduced cardiac output.
  • Vomiting commonly occurs within minutes. Use an individual fasting plan, protect the airway and position/recover the patient to reduce regurgitation and aspiration risk; fasting does not eliminate that risk.
  • Xylazine alone is not reliable surgical analgesia or general anaesthesia. For painful procedures provide local/general anaesthesia and multimodal analgesia, reducing all interacting sedative/anaesthetic doses to effect.
  • Other CNS depressants are additive. Do not combine with epinephrine or other sympathomimetics because ventricular arrhythmia may follow; reconcile every co-drug and avoid casual protocol substitution.
  • Do not use in late pregnancy because uterine contraction and premature labour may occur; earlier pregnancy requires explicit benefit–risk assessment. Anticipate hyperglycaemia and polyuria, especially when metabolic status matters.
  • An alpha-2 antagonist may reverse selected effects but does not erase aspiration, hypoxaemia, arrhythmia, temperature, fluid or co-anaesthetic risk. Calculate the antagonist protocol and continue monitoring for pain, haemodynamic change or re-sedation.
  • Prevent accidental self-injection, ingestion and skin/eye/mucosal exposure. After exposure seek urgent medical advice and do not drive; pregnant handlers need special caution. Store below 25°C, protect from light and discard 28 days after opening.
Assessment sources
  1. Rometar Czech SPC2026
  2. Rometar exact instruction2026
  3. Xylexx VMD control2025
  4. AnaSed FDA control1992
  5. AAHA anaesthesia 20202020
  6. ACVAA monitoring 20252025
  7. Feline metabolic effects2008
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Xylazine20 mg/ml
Formulation Type
Solution
Administration route
Intramuscular, Subcutaneous
Manufacturer
Bioveta a.s. · Czechia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: რომეტარი 20მგ/მლ
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ 99/192/85-C
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
Information not fully verified Veterinarian-administered sedation/premedication. Dog: 1–3 mg/kg IM once. Cat: 1–2 mg/kg IM or SC once; the upper limit may depress respiration. Use the lowest effective dose after examination; do not automatically top up. Painful procedures need local/general anaesthesia and multimodal analgesia. Plan fasting, anticholinergic use, airway support and recovery monitoring for the individual patient.

Xyla 20 mg/ml, Solution

xylazine 20 mg/ml, solution for injection
Composition / strength
Xylazine20 mg/ml
Formulation Type
Solution
Administration route
Intramuscular, Intravenous, Subcutaneous
Registration
Georgia Yes, veterinary
In force until 22 May 2028
Veterinary (National Food Agency)
In the register: ქსილა
№ 000289; 72-11
Verified on: 29 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026

Xylazin bio 2%, Solution

xylazine 20 mg/ml, solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Label-concordant IM or IV sedation and IM anaesthetic premedication in appropriately selected dogs, with balanced analgesia for painful procedures
6.7/10
Situational / acceptable
vetman assessment

Xylazin bio

2%, xylazine 20 mg/ml, solution for injection
Assessed clinical scopeDog · Label-concordant IM or IV sedation and IM anaesthetic premedication in appropriately selected dogs, with balanced analgesia for painful procedures · IM,IV
Care settingVeterinary-only administration after pre-anaesthetic assessment, exact weight/concentration/route calculation and independent double-check; airway, oxygen, cardiovascular/ventilation/temperature monitoring and supervised recovery immediately available
vetman score 6.7/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

A useful authorised IM/IV canine sedative with clear exact dose rows, but substantial alpha-2 risk and incomplete analgesia keep it conditional and fully monitored.

Regulatory and scientific credibility7.5/10

The exact 50 ml presentation has current Georgian registration and a valid Romanian stand-alone authorisation with transparent formulation, dog routes and dose ranges. One-country EU breadth and limited exact-product outcomes cap credibility.

Clinical efficacy7.0/10

Established xylazine pharmacology and direct canine studies support reliable dose-dependent sedation; exact IM and IV options add flexibility. Response varies, modern protocols often prefer more selective alpha-2 agonists, and xylazine is not dependable stand-alone surgical analgesia.

Safety and tolerability5.0/10

Bradycardia/AV block, biphasic blood pressure, reduced cardiac output, arrhythmia, respiratory depression, emesis, temperature change, hyperglycaemia and rare arrest require strict selection and full monitoring. IV dosing demands particularly controlled titration.

Clinical practicality7.5/10

Single IM or titratable IV administration and a familiar concentration are operationally useful, with distinct protocol rows already available. Accurate small-volume measurement, fasting/airway planning, combination reconciliation and fully staffed monitoring/recovery remain substantial.

Full-course cost-effectiveness-

Current Georgian full-course price and vial-wastage data were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Use only after examination in a monitored veterinary setting. Record exact weight, 20 mg/ml concentration, route, protocol-specific dose, co-drugs and times; do not interchange the IM, IV or premedication rows.
  • Do not use with GI obstruction, significant cardiac disease/ventricular arrhythmia, respiratory insufficiency, hepatic/renal impairment, seizure history, hypotension/shock or diabetes; avoid in puppies/kittens under six weeks.
  • Dog sedation is 1–2 mg/kg IM or 0.5–1 mg/kg IV once; ketamine premedication is a separate 1–2 mg/kg IM row. Use the lowest effective dose and never substitute one route/protocol range for another.
  • Monitor ECG/rhythm, heart rate, blood pressure, oxygenation, ventilation, temperature and sedation depth continuously through recovery. Bradycardia/AV block can be severe; pressure may rise then fall while cardiac output decreases.
  • Vomiting commonly occurs within minutes. Use an individual fasting plan, protect the airway and position/recover the patient to reduce regurgitation and aspiration risk; fasting does not eliminate that risk.
  • Xylazine alone is not reliable surgical analgesia or general anaesthesia. For painful procedures provide local/general anaesthesia and multimodal analgesia, reducing all interacting sedative/anaesthetic doses to effect.
  • Other CNS depressants are additive. Do not combine with epinephrine or other sympathomimetics because ventricular arrhythmia may follow; reconcile every component of ketamine protocols before administration.
  • Brachycephalic airway disease can cause life-threatening dyspnoea; deep-chested breeds may bloat. Pregnancy requires benefit–risk assessment and late-pregnancy use is contraindicated except at parturition.
  • Alpha-2 antagonism may reverse selected effects but does not erase aspiration, hypoxaemia, arrhythmia, temperature, fluid, pain or co-anaesthetic risk. Calculate the reversal protocol and continue monitoring for haemodynamic change or re-sedation.
  • Prevent self-injection, ingestion and skin/eye/mucosal exposure; seek urgent medical advice after exposure and do not drive. Track opening/sterility of the multidose vial, store per label and do not use a contaminated or expired vial.
Assessment sources
  1. Xylazin bio Romanian SPC2021
  2. Xylazin bio exact2026
  3. Xylazin Rometar relation2026
  4. Xylexx VMD control2025
  5. AnaSed FDA control1992
  6. AAHA anaesthesia 20202020
  7. ACVAA monitoring 20252025
  8. Canine cardiopulmonary1975
  9. Canine xylazine ketamine1986
  10. Canine antagonism2009
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Label-concordant IM or SC sedation and IM anaesthetic premedication in appropriately selected cats, using the reconciled mg/kg dose and balanced analgesia
5.6/10
Weak evidence support
vetman assessment

Xylazin bio

2%, xylazine 20 mg/ml, solution for injection
Assessed clinical scopeCat · Label-concordant IM or SC sedation and IM anaesthetic premedication in appropriately selected cats, using the reconciled mg/kg dose and balanced analgesia · IM,SC
Care settingVeterinary-only administration after pre-anaesthetic assessment, exact weight/concentration/route calculation and independent double-check; airway, oxygen, cardiovascular/ventilation/temperature monitoring and supervised recovery immediately available
vetman score 5.6/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · Verified on 22 Oct 2026

The intended feline mg/kg regimen is pharmacologically plausible, but an official twofold volume contradiction creates a serious preventable dosing hazard and materially weakens the exact product.

Regulatory and scientific credibility6.5/10

The exact presentation is registered in Georgia and Romania with transparent formulation, but its official cat text contains a twofold conflict between 1–2 mg/kg and 0.1–0.2 ml/kg at 20 mg/ml. Reconciliation is possible, yet this material medication-error defect lowers exact-label credibility.

Clinical efficacy6.5/10

The valid exact authorisation and established alpha-2 effect support feline sedation, but modern direct feline outcomes are limited. The intended mg/kg range is plausible; efficacy does not validate the contradictory printed volume or make xylazine complete anaesthesia.

Safety and tolerability4.0/10

The same major alpha-2 cardiopulmonary, emetic, metabolic and reproductive hazards apply, while the label volume conflict could double the intended feline dose. Independent mg/kg-to-volume calculation and double-check are hard safety requirements, not optional clarification.

Clinical practicality5.5/10

A single IM/SC injection is physically simple, but the official twofold volume discrepancy makes routine use error-prone. Small-volume measurement, an independent calculation/double-check, vomiting/airway preparation, combination reconciliation and full recovery monitoring impose high clinical burden.

Full-course cost-effectiveness-

Current Georgian full-course price and vial-wastage data were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Dosing conflict: use 1–2 mg/kg, which equals 0.05–0.1 ml/kg at 20 mg/ml. Do not use the Romanian SPC printed 0.1–0.2 ml/kg because it equals 2–4 mg/kg. Independently calculate and double-check before injection.
  • Do not use with GI obstruction, significant cardiac disease/ventricular arrhythmia, respiratory insufficiency, hepatic/renal impairment, seizure history, hypotension/shock or diabetes; avoid in puppies/kittens under six weeks.
  • Cat sedation is 1–2 mg/kg IM/SC once after resolving the volume conflict; ketamine premedication is a separate lower 0.5–1 mg/kg IM row. Do not merge these protocol doses or automatically repeat.
  • Monitor ECG/rhythm, heart rate, blood pressure, oxygenation, ventilation, temperature and sedation depth continuously through recovery. Bradycardia/AV block can be severe; pressure may rise then fall while cardiac output decreases.
  • Vomiting commonly occurs within minutes. Use an individual fasting plan, protect the airway and position/recover the patient to reduce regurgitation and aspiration risk; fasting does not eliminate that risk.
  • Xylazine alone is not reliable surgical analgesia or general anaesthesia. For painful procedures provide local/general anaesthesia and multimodal analgesia, reducing all interacting sedative/anaesthetic doses to effect.
  • Other CNS depressants are additive. Do not combine with epinephrine or other sympathomimetics because ventricular arrhythmia may follow; reconcile every component of ketamine protocols before administration.
  • Do not use in late pregnancy because uterine contraction and premature labour may occur; earlier pregnancy requires explicit benefit–risk assessment. Anticipate hyperglycaemia and polyuria.
  • Alpha-2 antagonism may reverse selected effects but does not erase aspiration, hypoxaemia, arrhythmia, temperature, fluid, pain or co-anaesthetic risk. Calculate the reversal protocol and continue monitoring for haemodynamic change or re-sedation.
  • Prevent self-injection, ingestion and skin/eye/mucosal exposure; seek urgent medical advice after exposure and do not drive. Track opening/sterility of the multidose vial, store per label and do not use a contaminated or expired vial.
Assessment sources
  1. Xylazin bio Romanian SPC2021
  2. Xylazin bio exact2026
  3. Xylazin Rometar relation2026
  4. Xylexx VMD control2025
  5. AnaSed FDA control1992
  6. AAHA anaesthesia 20202020
  7. ACVAA monitoring 20252025
  8. Feline metabolic effects2008
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Xylazine20 mg/ml
Formulation Type
Solution
Administration route
Intravenous, Intramuscular, Subcutaneous
Manufacturer
Bioveta a.s. · Czechia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ქსილაზინი ბიო 2%
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ 150180
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
Information not fully verified Veterinarian-administered sedation/premedication. Dog sedation: 1–2 mg/kg IM or 0.5–1 mg/kg IV once. Cat sedation: use 1–2 mg/kg IM/SC, which equals 0.05–0.1 ml/kg; reject the internally conflicting 0.1–0.2 ml/kg printed in the Romanian SPC. Separate ketamine-premedication rows are dog 1–2 mg/kg IM and cat 0.5–1 mg/kg IM. Independently calculate, double-check and monitor every dose.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 29 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗